PAT101

PAT101 is a recombinant human albumin (rHA)-conjugated urate oxidase variant being developed by ProAbTech for the treatment of gout and other metabolic conditions. The drug is produced using ProAbTech's proprietary SelecAll™ and Albubody™ platforms, which facilitate the site-specific conjugation of recombinant human albumin to an *Aspergillus flavus* urate oxidase (AfUox) through a clickable non-natural amino acid (frTet) and an Inverse electron demand Diels–Alder (IEDDA) reaction. This albumin-conjugation strategy is designed to extend the therapeutic half-life and reduce the immunogenicity typically associated with PEGylated urate oxidase treatments like pegloticase. Preclinical data in transgenic mice demonstrated that PAT101 has a half-life more than double that of pegloticase. It is currently in Phase 1 clinical development for gout, congenital disorders, and endocrinology/metabolic conditions.

Other names

Albumin-conjugated urate oxidaserHA-conjugated urate oxidase variant